ISOPLEXIS platform for single cell multiplexed functional proteomics of immune cells

Background

The immune system naturally functions to defend the body against infection. In autoimmune diseases (e.g. diabetes), the immune system mistakenly recognises and attacks normal cells. In contrast, where cancer develops, the immune system fails to recognise or attack abnormal cells. Technology which provides a deeper understanding of how immune cells function will be critical to scientists developing better treatments for autoimmune disease and cancer.

Approach

This funding proposal is for a novel, state-of-the-art technology (IsoPlexis/IsoLIght) that will allow researchers across UCL to study how the immune system functions in health and disease in a way that has not previously been possible.

Expected Impact

At a single-cell level and across a wide range of diseases, the Isoplexis/IsoLight will help researchers begin to understand how immune cells can lose normal function, and we expect that these new insights will inform the development of better treatments for infection, autoimmunity and cancer.